Dr. Michael Boyle is an Adjunct Professor of Medicine at the Johns Hopkins University School of Medicine. His areas of expertise include adult cystic fibrosis care and research, lung transplantation and pulmonary diseases. Dr. Boyle founded and then directed the Johns Hopkins Adult Cystic Fibrosis Program from 1999 to 2015 at the Johns Hopkins Cystic Fibrosis Center. He is now Senior Vice President for Therapeutics Development at the U.S. Cystic Fibrosis Foundation and Adjunct Johns Hopkins faculty member. His research is focused on clinical trials for the development of new cystic fibrosis therapies. Dr. Boyle completed all of his medical training at Johns Hopkins including fellowship in pulmonary and critical care medicine before joining the Johns Hopkins faculty in 1999. He is internationally known both for his clinical research in CFTR modulators and for his work to improve care for adults with cystic fibrosis. While at Johns Hopkins he has received numerous honors including the American Lung Association’s George Comstock Career Achievement Award, American Federation of Clinical Research Achievement Award, “Patient’s Choice Award”, “Best Teacher”, and “Best Doctors in America”. MD, Johns Hopkins University School of Medicine (1991)

CFTR Modulators; Cystic Fibrosis Clinical Trials; Difficult to Treat Infections in Cystic Fibrosis

Dr. Boyle is internationally known for his clinical research in both CFTR modulators and difficult to treat lung infections.  He has been the principal investigator for international clinical trials of CFTR modulator therapies which resulted in approval of new therapies for individuals with cystic fibrosis.

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 373:220-31, 2015. PMID: 25981758 Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D. on behalf of the VX09-809-102 Study Group. Randomised Trial of Combined CFTR Corrector and Potentiator Therapy in F508del-CFTR Cystic Fibrosis. The Lancet – Respiratory Medicine. 2: 527-38, 2014. PMID: 24973281 Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association of Respiratory Tract Methicillin-Resistant Staphylococcus Aureus and Survival in Cystic Fibrosis. JAMA 303:2386-92, 2010. PMID: 20551409 Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent Methicillin-resistant Staphylococcus Aureus and Rate of FEV1 Decline in Cystic Fibrosis. Am J Respir Crit Care Med 178:814-821; 2008. PMID: 18669817 Boyle MP, Sabadosa KA, Quinton HB, Marshall BC, Schechter MS. Key Findings of the Cystic Fibrosis Foundation's U.S. Clinical Practice Benchmarking Project. BMJ Quality and Safety. 23:15-22, 2014. PMID: 24608546